Aburisheh Khaled H, Enabi Hamza M K, Alodah Nora A, Alotary Bassam H, Algheryafi Linah A, Almairi Ayman M, Aldhewaila Amani A
University Diabetes Center, King Saud University Medical City, King Saud University, Riyadh, Saudi Arabia.
Alfaisal University, Riyadh, Saudi Arabia.
J Med Cases. 2024 Dec;15(12):367-370. doi: 10.14740/jmc4307. Epub 2024 Oct 30.
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated with an increased morbidity and mortality worldwide. Coronavirus disease 2019 (COVID-19) vaccines have shown high efficacy in preventing the infection but with many possible side effects such as hyperglycemia. New-onset diabetes mellitus (DM) and severe metabolic complications have been reported post-vaccination. Here we report a 45-year-old woman who came to the hospital complaining of polyurea, polydipsia, and weight loss 3 weeks after the first activation dose of COVID-19 vaccine. Her hemoglobin A1c (HbA1c) upon presentation was 9% without any prior history of DM. She was diagnosed with type 1 diabetes mellitus (T1DM), as the anti-glutamic acid decarboxylase (GAD) antibody was positive and complicated during follow-up with diabetic ketoacidosis (DKA). This is the first case in Saudi Arabia suggesting that the COVID-19 RNA-based vaccines might cause new onset of T1DM, complicated by late DKA.
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染在全球范围内导致发病率和死亡率上升。2019冠状病毒病（COVID-19）疫苗在预防感染方面显示出高效性，但存在许多可能的副作用，如高血糖。接种疫苗后有新发糖尿病（DM）和严重代谢并发症的报道。在此，我们报告一名45岁女性，在接种第一剂COVID-19疫苗激活剂量3周后因多尿、多饮和体重减轻前来就诊。她就诊时糖化血红蛋白（HbA1c）为9%，既往无DM病史。她被诊断为1型糖尿病（T1DM），因为抗谷氨酸脱羧酶（GAD）抗体呈阳性，且在随访期间并发糖尿病酮症酸中毒（DKA）。这是沙特阿拉伯的首例病例，提示基于COVID-19 RNA的疫苗可能导致新发T1DM，并伴有迟发性DKA。
